Estimated 10-year ASCVD risk was significantly associated with future cancer, demonstrating a 16% increased hazard per 5% increase in risk.
Cohort (n=20,305)
Yes
Are standard CVD risk factors, ASCVD risk score, and CVD biomarkers associated with the development of future cancer in individuals free of cancer and major CVD at baseline?
Traditional cardiovascular risk factors, higher 10-year ASCVD risk scores, and elevated natriuretic peptides are associated with an increased risk of future incident cancer, suggesting shared risk factors between the two diseases.
Effect estimate: HR 1.16 (95% CI 1.14 to 1.17)
p-value: p=<0.001
BACKGROUND: The extent to which co-occurrence of cardiovascular disease (CVD) and cancer is due to shared risk factors or other mechanisms is unknown. OBJECTIVES: We investigated the association of standard CVD risk factors, CVD biomarkers, preexisting CVD, and ideal CV health metrics with the development of future cancer. METHODS: We prospectively followed Framingham Heart Study and PREVEND participants free of cancer at baseline, and ascertained histology-proven cancer. We studied the association of baseline CV risk factors, 10-year atherosclerotic CVD risk score, established CVD biomarkers, prevalent CVD, and AHA Life's Simple 7 CV health score with incident cancer using multivariable Cox models. Analyses of interim CVD events with incident cancer used time-dependent covariates. RESULTS: Among 20,305 participants (mean age 50 ± 14 years, 54% women), 2,548 incident cancer cases occurred over a median follow-up of 15.0 (13.3-15.0) surveillance years. Traditional CVD risk factors including age, sex, and smoking status were independently associated with cancer (P <0.001 for all). Estimated 10-year atherosclerotic CVD risk was also associated with future cancer (HR 1.16 per 5% increase in risk, 95% CI 1.14-1.17, P<0.001). We found that natriuretic peptides (NP) (tertile 3 vs 1: HR 1.40, 95% CI 1.03-1.91, p=0.035) was associated with incident cancer, but not high sensitivity troponin (hs-cTn) (p=0.47). Prevalent CVD and the development of interim CV events were not associated with higher risk of subsequent cancer. However, ideal CV health was associated with lower future cancer risk (HR 0.95 per 1-point increase in AHA health score, 95% CI 0.92-0.99, p=0.009). CONCLUSIONS: CVD risk as captured by traditional CVD risk factors, 10-year atherosclerotic CVD risk score, and NP concentrations are associated with increased risk of future cancer. Conversely, a heart healthy lifestyle is associated with a reduced risk of future cancer. Our data suggest that the association between CVD and future cancer is attributable to shared risk factors.
Lau et al. (Mon,) conducted a cohort in Healthy individuals free of cancer at baseline (n=20,305). 10-year ASCVD risk score vs. Lower ASCVD risk was evaluated on Incident cancer (HR 1.16, 95% CI 1.14 to 1.17, p=<0.001). Estimated 10-year ASCVD risk was significantly associated with future cancer, demonstrating a 16% increased hazard per 5% increase in risk.